BusinessAbeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIBBy Nasdaq OMXDec 20, 2017, 1:45 PM UTC
BusinessAbeona Reports Third Quarter 2017 Financial Results and Recent Business HighlightsBy Nasdaq OMXNov 15, 2017, 1:25 PM UTC
BusinessAbeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene TherapiesBy Nasdaq OMXOct 16, 2017, 12:26 PM UTC
BusinessAbeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the MesaBy Nasdaq OMXOct 6, 2017, 12:25 PM UTC
